Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been prescribed ONAPGO™ by their doctor as part of their regular care.
- People who have agreed to receive support from a Clinical Nurse Navigator — a registered nurse with specialist training in Parkinson's disease — as noted on their prescription enrollment form.
- People whose doctor has determined that taking part in the study is appropriate for them.
- People who are able and willing to sign a consent form on the day they enrol in the study.
Who may not be able to join:
- People who have not been prescribed ONAPGO™.
- People who have been prescribed ONAPGO™, but whose doctor has decided that participation in this observational study is not appropriate for them.
- People who are taking certain other medicines at the same time as ONAPGO™ — specifically a group of drugs called 5-HT3 antagonists, which includes some anti-nausea medications such as ondansetron, granisetron, dolasetron, palonosetron, or alosetron (confirm with trial site if unsure whether a current medication falls into this category).
- People who have a known allergy or sensitivity to apomorphine or to any ingredient in ONAPGO™, including sulfites such as sodium metabisulfite.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mindy Grall, PhD ANP-BC, Supernus Pharmaceuticals, Inc.
Phone: 18663980833
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Titration Duration and Time to Optimized Dose; Concomitant Parkinson's Disease (PD) Medication Adjustments; The number of titration visits or dose adjustments required to reach the final optimized dose. This is a count of a specific event
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.